Navigation Links
Synthetic protein found to relieve arthritis symptoms in animal model

A synthetic version of a human protein has been found to alleviate symptoms associated with acute and chronic arthritis in mice, which could be the basis for developing a new drug for the disease, according to researchers. // The protein has been found to function by blocking the transmission of chemical signals associated with development of arthritis symptoms.

The idea that the protein, called pre-ligand assembly domain protein or PLAD, might play a role in easing or comforting pain characteristic of rheumatoid arthritis is an incidental discovery. The original work was carried out on a very rare autoimmune disease called autoimmune lymphoproliferative syndrome (ALPS).

Previously, it has been shown that PLAD blocks a cell surface receptor and prevents a needed chemical signaling pathway from functioning correctly. In ALPS, the signal pathway interrupted by PLAD leads to disease symptoms. But, the scientists reasoned, PLAD might also be able to block a related cell surface receptor one involved in passing signals, leading to inflammation. In theory, inhibiting this pathway might benefit people with rheumatoid arthritis, who suffer from excessive inflammation.

The scientists used a variety of techniques to induce arthritis symptoms in mice. Researchers also injected some of the animals with lab-made PLAD (P60 PLAD). It was found that P60 PLAD protein powerfully inhibited the symptoms of TNF-alpha-induced arthritis (a key promoter of inflammation is a chemical called tumor necrosis factor alpha- TNF-alpha). Moreover, it also appeared to inhibit disease symptoms in mice with established as well as acute arthritis. The scientists did not detect any obvious toxicity in the PLAD-treated mice.

The scientist’s next aim is to develop a more stable form of P60 PLAD to be followed by testing of the protein in clinical trials. This study opens a new research avenue to better understand and, perhaps, to treat rheumatoid arthritis, according to those who believe that a treatment for rheumatoid arthritis is not far way.
'"/>




Related medicine news :

1. New Study Will The Look Into The Effects Of Synthetic Steroids
2. Synthetic Bone Tissue Could Be the Answer to Disfigurement Caused by Oral Cancer
3. A Synthetic Molecule Instigates Cancer Cells To Self-Harm
4. Synthetic DNA Makes Better Hydrogels for Drug Delivery
5. Super Chow, Laced With Semi-Synthetic Vitamin E, Inhibited Spread of Cancer
6. Synthetic Chemicals May Trigger Breast Cancer
7. Synthetic Cannabinoid Could Improve Fertility in Smokers
8. Chemicals Used To Make Synthetic Color Can Cause Cancer And Permanent Blindness
9. Special proteins to fight TB identified
10. High-protein diets may pose health risks
11. Hidden influenza virus protein found
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: